Sou FM, Hsu CN, Chiu YC, Wu CK, Lu LS, Kuo CM, Chiu SM, Chuah SK, Yang YH, Liang CM*. The association between trajectory of serum cholesterol, statin dosage, and the risk of recurrent biliary stone diseases. J Formos Med Assoc. 2024 Apr 7:S0929-6646(24)00203-1. (SCI)
Tai WC, Wu IT, Wang HM, Huang PY, Yao CC, Wu CK, Yang SC, Liang CM*, Hsu PI, Chuah SK. The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan. J Microbiol Immunol Infect. 2024 Aug;57(4):601-608. (SCI)
Wang HM, Huang PY, Yang SC, Wu MK, Tai WC, Chen CH, Yao CC, Lu LS, Chuah SK, Lee YC*, Liang CM*. Correlation between Psychosomatic Assessment, Heart Rate Variability, and Refractory GERD: A Prospective Study in Patients with Acid Reflux Esophagitis. Life (Basel). 2023 Sep 3;13(9):1862. (SCI)
Tai WC, Yang SC, Yao CC, Wu CK , Liu AC, Lee CH, Kuo YH, Chuah SK*, Liang CM*. The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naive Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial. Infect Dis Ther. 2023 May;12(5):1415-1427. (SCI)
Ma TL, Tai WC, Loke SS, Yao CC, Liang CM*, Chuah SK. Efficacy and Safety of 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Helicobacter pylori Eradication in the Elderly. Drugs Aging. 2023 Jan;40(1):71-79. (SCI)
Liang CM, Chiu YC, Lu LS, Wu CK, Sou FM, Chiu SM, Lee YC, Huang PY, Chuah SK, Kuo CM*. Early and Direct Endoscopic Stone Removal in the Moderate Grade of Acute Cholangitis with Choledocholithiasis Was Safe and Effective: A Prospective Study. Life (Basel). 2022 Nov 30;12(12):2000. (SCI)
Wu CK, Hsu CN, Cho WR, Yang SC, Liu AC, Tai WC, Lee CH, Yang YH, Chuah SK, Liang CM*. Increased Risk of Pyogenic Liver Abscess after Endoscopic Sphincterotomy for Treatment of Choledocholithiasis. Infect Drug Resist. 2021 Jun 8; 14:2121-2131. (SCI)
Hung KT, Yang SC, Wu CK, Wang HM, Yao CC, Liang CM*, Tai WC, Wu KL, Kuo YH, Lee CH, Chuah SK*. Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice. Infect Drug Resist. 2021 Mar; 2021(14):1239-1246. (SCI)
Hung KT, Kuo CM, Tsai CE, Chiu YC, Lu LS, Wu CK, Sou FM, Huang PY, Tai WC, Kuo CH, Liang CM*, Chuah SK. Single-stage retrograde endoscopic common bile duct stone removal might be sufficient in moderate acute cholangitis with a stone size ?12?mm: A retrospective cohort study with propensity score matching. Adv Dig Med. 2020 Dec;7(4):188–194. (台灣消化醫學雜誌)
Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY*, Chuah SK*. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol
. 2020 Dec 10;13:1756284820976990. (SCI)
Liang CM, Yang SC, Wu CK, Li YC, Yeh WS, Tai WC, Lee CH, Yang YH, Tsai TH, Hsu CN*, Chuah SK*. Risk of Recurrent Peptic Ulcer Disease in Patients Receiving Cumulative Defined Daily Dose of Nonsteroidal Anti-Inflammatory Drugs. J Clin Med. 2019 Oct; 8(10): 1722. (SCI)
Yao CC, Kuo CM, Hsu CN, Yang SC, Wu CK, Tai WC, Liang CM*, Wu KL, Huang CF, Bi KW, Lee CH, Chuah SK. First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus. Infect Drug Resist. 2019 May 29;12:1425-1431. (SCI)
Liang CM, Kuo CM*, Lu LS, Wu CK, Tsai CE, Kuo MT, Chiu YC*, Tai WC, Kuo YH, Kuo CH, Chuah SK, Changchien CS. A comparison between non-sedation and general endotracheal anesthesia for retrograde endoscopic common bile duct stone removal: A tertiary center experience. Biomed J. 2019 Apr;42(2):131-136. (SCI)
Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM*, Wang YK, Wang JW, Huang CF, Chuah SK; Taiwan Acid-Related Disease Study Group. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial. Drug Des Devel Ther. 2019 Apr 26;13:1347-1356. (SCI)
Huang HT, Wang HM, Yang SC, Tai WC, Liang CM*, Wu KL, Lee CH, Chuah SK. Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication. Infect Drug Resist. 2018 Oct 30;11:2073-2080. (SCI)
Liang CM, Chiu CH, Wang HM, Tai WC, Yao CC,Tsai CE, Kuo CM, Chiu YC, Wu KL, Lee CH*, Tsai KL, Huang CF, Chuah SK*. First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan. Biomed Res Int. 2017;2017:3762194. (SCI)
Liang CM(co-first), Kuo MT(co-first), Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK*, Taiwan Acid-Related Disease Study Group. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol. 2017 Dec 21; 23(47): 8395-8404. (SCI)
Liang CM, Hsu CN, Tai WC, Yang SC, Wu CK, Shih CW, Ku MK, Yuan LT, Wang JW, Tseng KL, Sun WC, Hung TH, Nguang SH, Hsu PI, Wu DC*, Chuah SK*; Taiwan Acid-Related Disease (TARD) Study Group. Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study. Medicine (Baltimore). 2016 Sep;95(36):e4795. (SCI)
Chuah SK(co-first), Liang CM(co-first), Lee CH, Chiou SS, Chiu YC, Hu ML, Wu KL, Lu LS, Chou YP, Chang KC, Kuo CH, Kuo CM, Hu TH, Tai WC*. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication. Medicine (Baltimore). 2016 May;95(19):e3586. (SCI)
Tai WC, Liang CM(co-first), Lee CH, Chiu CH, Hu ML, Lu LS, Kuo YH, Kuo CM, Yen YH, Kuo CH, Chiou SS, Wu KL, Chiu YC, Hu TH, Chuah SK*. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A” Success Rate for First-Line Helicobacter pylori Eradication. Biomed Res Int. 2015 Jan;2015:623732. (SCI)
Liang CM, Cheng JW(co-first), Kuo CM, Chang KC, Wu KL, Tai WC*, Chiu KW, Chiou SS, Lin MT, Hu TH, Chuah SK. Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. Biomed J. 2014 Sep-Oct.37(5):326-330. 長庚醫誌
Liang CM, Hu TH, Lu SN, Hung CH*, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC, Kuo YH, Lee CM. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. J Viral Hepat. 2013 Nov.; 20(11):761-769. (SCI)
Liang CM, Chiu YC, Wu KL*, Tam W, Tai WC, Hu ML, Chou YP, Chiu KW, Chuah SK. Impact factors for difficult cecal intubation during colonoscopy. Surg Laparosc Endosc Percutan Tech. 2012 Oct;22(5):443-6. (SCI)
Liang CM, Lee JH (co-first), Kuo YH, Wu KL, Chiu YC, Chou YP, Hu ML, Tai WC, Chiu KW, Hu TH, Chuah SK*. Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis. BMC Gastroenterol. 2012 Mar 28;12:28. (SCI)
Liang CM, Wu KL, Chou YP, Tai WC*, Chiu YC, Changchien CS, Chiou SS, Hu TH, Chuah SK. Prevalence and Associated Factors of Hyperechoic Pancreas on Sonography. Gastroenterol J Taiwan. 2011 Sept; 28(3): 281-288.
Liang CM, Wang MC, Chen YJ, Hung CH*, Hu TH. Primary Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma: Report of a Case. Gastroenterol J Taiwan 2011 Sept; 28(3):310-316.
